Login to Your Account



Top-line diabetes data weigh on Vitae's shares

By Michael Fitzhugh
Staff Writer

Monday, June 29, 2015
A type 2 diabetes drug discovered by Vitae Pharmaceuticals Inc. and partnered with Boehringer Ingelheim GmbH failed to meet Boehringer's primary efficacy endpoint – change in fasting plasma glucose – when combined with the common diabetes medicine metformin in an ongoing phase II study.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription